866-997-4948(US-Canada Toll Free)

Cancer Pain Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Cancer

No. of Pages : 139 Pages


Global Markets Directs, \'Cancer Pain Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. 

Cancer Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Pain.
  • A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Pain pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Pain Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cancer Pain 9
Cancer Pain Therapeutics under Development by Companies 11
Cancer Pain Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Cancer Pain Therapeutics Products under Development by Companies 20
Cancer Pain Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Cancer Pain Therapeutics Development 24
Amgen Inc. 24
BioDelivery Sciences International, Inc. 25
Daiichi Sankyo Company, Ltd 26
Sangamo BioSciences, Inc. 27
Egalet a/s 28
Ipsen S.A. 29
Aphios Corporation 30
AcelRx Pharmaceuticals, Inc. 31
Nippon Kayaku Co., Ltd. 32
Nippon Shinyaku Co., Ltd. 33
Pfizer Inc. 34
Taiho Pharmaceutical Co., Ltd. 35
GW Pharmaceuticals plc 36
IntelGenx Technologies Corp. 37
Benitec Ltd. 38
NovaDel Pharma, Inc. 39
Diamyd Medical AB 40
ProStrakan Group plc 41
BCN Peptides S.A. 42
Phosphagenics Limited 43
Grunenthal GmbH 44
AngioChem Inc. 45
WEX Pharmaceuticals Inc. 46
QRxPharma Limited 47
APEIRON Biologics AG 48
Winston Pharmaceuticals, Inc. 49
Encore Therapeutics Inc. 50
Afferent Pharmaceuticals, Inc. 51
Cancer Pain Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
tanezumab - Drug Profile 58
fentanyl citrate - Drug Profile 60
BIM-46187 - Drug Profile 61
Sativex - Drug Profile 62
dronabinol - Drug Profile 65
fentanyl citrate - Drug Profile 66
fentanyl citrate - Drug Profile 68
fentanyl citrate - Drug Profile 70
Tectin - Drug Profile 71
ZFP TFs For Neuropathic Pain - Drug Profile 73
(morphine sulfate + oxycodone) CR - Drug Profile 74
ARX-02 Sufentanil NanoTab - Drug Profile 76
morphine sulfate ER - Drug Profile 78
fulranumab - Drug Profile 79
NP-2 - Drug Profile 81
ANG-2002 - Drug Profile 83
P2X3 Targeted Program - Drug Profile 84
methadone - Drug Profile 85
tramadol hydrochloride - Drug Profile 86
fentanyl citrate - Drug Profile 88
TK-641 - Drug Profile 89
zucapsaicin Sterile Solution - Drug Profile 90
DEX-IN - Drug Profile 91
THA-901 - Drug Profile 92
ddRNAi Program For Cancer-Associated Pain - Drug Profile 93
APN-601 - Drug Profile 95
tapentadol ER - Drug Profile 97
leconotide - Drug Profile 100
IPTRK-3 - Drug Profile 101
hydromorphone hydrochloride - Drug Profile 102
buprenorphine hydrochloride - Drug Profile 103
AF-353 - Drug Profile 104
dronabinol Advanced Formulation - Drug Profile 106
NRT-12 - Drug Profile 107
DD-04107 - Drug Profile 108
QX-314 - Drug Profile 109
ifenprodil - Drug Profile 110
Calpastatin Peptide - Drug Profile 111
oxymorphone hydrochloride - Drug Profile 112
Drug For Pancreatic Cancer Pain - Drug Profile 113
Cancer Pain Therapeutics Drug Profile Updates 114
Cancer Pain Therapeutics Discontinued Products 127
Cancer Pain Therapeutics - Dormant Products 128
Cancer Pain Product Development Milestones 130
Featured News & Press Releases 130

Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 136
Disclaimer 136

List of Table


Number of Products Under Development for Cancer Pain, H1 2013 12
Products under Development for Cancer Pain Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Development by Companies, H1 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Amgen Inc., H1 2013 27
BioDelivery Sciences International, Inc., H1 2013 28
Daiichi Sankyo Company, Ltd, H1 2013 29
Sangamo BioSciences, Inc., H1 2013 30
Egalet a/s, H1 2013 31
Ipsen S.A., H1 2013 32
Aphios Corporation, H1 2013 33
AcelRx Pharmaceuticals, Inc., H1 2013 34
Nippon Kayaku Co., Ltd., H1 2013 35
Nippon Shinyaku Co., Ltd., H1 2013 36
Pfizer Inc., H1 2013 37
Taiho Pharmaceutical Co., Ltd., H1 2013 38
GW Pharmaceuticals plc, H1 2013 39
IntelGenx Technologies Corp., H1 2013 40
Benitec Ltd., H1 2013 41
NovaDel Pharma, Inc., H1 2013 42
Diamyd Medical AB, H1 2013 43
ProStrakan Group plc, H1 2013 44
BCN Peptides S.A., H1 2013 45
Phosphagenics Limited, H1 2013 46
Grunenthal GmbH, H1 2013 47
AngioChem Inc., H1 2013 48
WEX Pharmaceuticals Inc., H1 2013 49
QRxPharma Limited, H1 2013 50
APEIRON Biologics AG, H1 2013 51
Winston Pharmaceuticals, Inc., H1 2013 52
Encore Therapeutics Inc., H1 2013 53
Afferent Pharmaceuticals, Inc., H1 2013 54
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Stage and Molecule Type, H1 2013 60
Cancer Pain Therapeutics Drug Profile Updates 117
Cancer Pain Therapeutics Discontinued Products 130
Cancer Pain Therapeutics Dormant Products 131
Cancer Pain Therapeutics Dormant Products (Contd..1) 132

List of Chart


Number of Products under Development for Cancer Pain, H1 2013 12
Products under Development for Cancer Pain Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Route of Administration, H1 2013 57
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Molecule Type, H1 2013 59
Assessment by Stage and Molecule Type, H1 2013 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *